We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Rapid Olfactory Test Shows Potential as Screening Tool for COVID-19

By LabMedica International staff writers
Posted on 20 Jul 2021
A study that evaluated the feasibility of a novel, objective olfactory test as part of an initial screening for COVID-19 in adults with unknown disease status has concluded that olfactory dysfunction (OD) is one of the earliest and strongest predictors of COVID-19 infection, and thus is promising as a disease screening tool.

In the prospective, cross-sectional study, researchers at University of California, San Diego (La Jolla, CA, USA) enrolled healthy adults (aged ≥ 18 years) from a single college campus COVID-19 screening site. More...
Participants were screened for OD using a novel scent card (SAFER Diagnostics) followed immediately by polymerase chain reaction (PCR) testing for SARS-CoV-2 from nasopharyngeal swabs. The SAFER card contained a single scent in a scratch-and-sniff label that the participant identified from 8 answer options: lemon, grape, floral, blueberry, banana, mint, unsure, or no scent. Answers were processed electronically via a QR code. An incorrect choice was classified as OD. Participant demographics, medical history, COVID-19 symptoms, and subjective smell function on a binary and 10-point visual analog scale (VAS, with 0 indicating no sense of smell and 10 indicating normal sense of smell) were also collected.

A total of 163 participants were prospectively screened for OD using the scent card followed by SARS-CoV-2 PCR testing. Of those who tested PCR-positive for COVID-19, 75% (12 out of 16) failed olfactory screening compared with 4.8% (7 out of 147) among those testing PCR-negative for COVID-19. The sensitivity, specificity, positive predictive value, and negative predictive value of the scent card in detecting those with COVID-19 were 75.0%, 95.2%, 63.2%, and 97.2%, respectively. Including the symptom fatigue along with OD achieved 93.8% sensitivity and 89.8% specificity in disease screening. The addition of fever and cough did not further increase sensitivity.

While only 37.5% (6 out of 16) of COVID-19 test-positive participants reported subjective anosmia, 75% failed screening with the scent card. A failed scent card screen was the greatest predictor of COVID-19 positivity (odds ratio [OR], 80.24; 95% CI, 14.77-435.90) when compared with other symptoms including cough, fever, fatigue, and a history of COVID-19 exposure. Thus, the study demonstrated that a rapid psychophysical olfaction test is feasible as a screening tool for COVID-19.

Related Links:
University of California, San Diego


Gold Member
SARS-CoV-2 PCR Test
Macurra SARS-CoV-2 PCR Kit
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.